4DX Stock Overview
4DMedical Limited operates as a medical technology company in Australia and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
4DMedical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.58 |
| 52 Week High | AU$1.13 |
| 52 Week Low | AU$0.40 |
| Beta | 1.29 |
| 1 Month Change | -7.94% |
| 3 Month Change | -10.08% |
| 1 Year Change | -45.28% |
| 3 Year Change | -58.57% |
| 5 Year Change | n/a |
| Change since IPO | -62.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4DX | AU Healthcare Services | AU Market | |
|---|---|---|---|
| 7D | -3.3% | 0.07% | 0.5% |
| 1Y | -45.3% | 67.3% | 6.2% |
Return vs Industry: 4DX underperformed the Australian Healthcare Services industry which returned 67.3% over the past year.
Return vs Market: 4DX underperformed the Australian Market which returned 6.2% over the past year.
Price Volatility
| 4DX volatility | |
|---|---|
| 4DX Average Weekly Movement | 6.2% |
| Healthcare Services Industry Average Movement | 8.0% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: 4DX's share price has been volatile over the past 3 months.
Volatility Over Time: 4DX's weekly volatility has decreased from 14% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 131 | Andreas Fouras | 4dmedical.com |
4DMedical Limited operates as a medical technology company in Australia and the United States. It commercializes XV Technology, a four-dimensional lung imaging technology. The company also offers software as a service delivery model; XV lungs ventilation analysis software; Permetium, a preclinical imaging system which quantify regional changes in pulmonary function; and AccuVent 200, a small animal ventilator.
4DMedical Limited Fundamentals Summary
| 4DX fundamental statistics | |
|---|---|
| Market cap | AU$225.05m |
| Earnings (TTM) | -AU$30.83m |
| Revenue (TTM) | AU$1.03m |
217.6x
P/S Ratio-7.2x
P/E RatioIs 4DX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4DX income statement (TTM) | |
|---|---|
| Revenue | AU$1.03m |
| Cost of Revenue | AU$51.29k |
| Gross Profit | AU$973.93k |
| Other Expenses | AU$31.81m |
| Earnings | -AU$30.83m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.079 |
| Gross Margin | 95.00% |
| Net Profit Margin | -3,007.65% |
| Debt/Equity Ratio | 0% |
How did 4DX perform over the long term?
See historical performance and comparison